Ensign Peak Advisors
RARE icon

Ensign Peak Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Ensign Peak Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.71M Buy
290,818
+284,097
+4,227% +$7.06M 0.02% 444
2026
Q1 		$141K Sell
6,721
-243,850
-97% -$5.49M ﹤0.01% 1474
2025
Q4 		$5.76M Buy
250,571
+73,150
+41% +$2.41M 0.01% 498
2025
Q3 		$5.34M Buy
177,421
+141,350
+392% +$4.24M 0.01% 579
2025
Q2 		$1.31M Hold
36,071
– – ﹤0.01% 1091
2025
Q1 		$1.31M Buy
36,071
+6,850
+23% +$285K ﹤0.01% 1107
2024
Q4 		$1.23M Buy
29,221
+100
+0.3% +$4.96K ﹤0.01% 1195
2024
Q3 		$1.62M Hold
29,121
– – ﹤0.01% 1046
2024
Q2 		$1.2M Hold
29,121
– – ﹤0.01% 1172
2024
Q1 		$1.36M Sell
29,121
-1,469
-5% -$69.3K ﹤0.01% 1129
2023
Q4 		$1.46M Hold
30,590
– – ﹤0.01% 1103
2023
Q3 		$1.09M Hold
30,590
– – ﹤0.01% 1132
2023
Q2 		$1.41M Buy
30,590
+450
+1% +$20.9K ﹤0.01% 1015
2023
Q1 		$1.21M Hold
30,140
– – ﹤0.01% 1091
2022
Q4 		$1.4M Sell
30,140
-83,849
-74% -$3.3M ﹤0.01% 952
2022
Q3 		$4.72M Buy
113,989
+28,675
+34% +$1.47M 0.01% 534
2022
Q2 		$5.09M Buy
85,314
+70,614
+480% +$4.35M 0.01% 533
2022
Q1 		$1.07M Hold
14,700
– – ﹤0.01% 1157
2021
Q4 		$1.24M Buy
+14,700
New +$1.2M ﹤0.01% 1171

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Ensign Peak Advisors's RARE Position: Q2 2026 in Review

Ensign Peak Advisors increased its Ultragenyx Pharmaceutical (RARE) stake by 4,227% in Q2 2026, buying an estimated $7.06M and bringing the position to 290,818 shares worth $9.71M. The position accounts for 0.02% of the portfolio, ranked #444.

Ensign Peak Advisors first reported a position in RARE in Q4 2021 and has held it in 19 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Ensign Peak Advisors held 290,818 shares of Ultragenyx Pharmaceutical worth $9.71M as of Q2 2026.
  • Ensign Peak Advisors bought 284,097 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $7.06M.
  • Ultragenyx Pharmaceutical made up 0.02% of Ensign Peak Advisors's portfolio in Q2 2026, its #444 holding.
  • Ensign Peak Advisors first reported a position in Ultragenyx Pharmaceutical in Q4 2021 and has held it in 19 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.